Matching articles for "ibuprofen"
Issue 1752 · April 13, 2026
Pivmecillinam (Pivya) for Uncomplicated UTI

The FDA has approved pivmecillinam ( Pivya – Utility Therapeutics), an oral penicillin-class antibacterial drug, for treatment of uncomplicated urinary tract infections (uUTIs) caused by susceptible isolates…

Med Lett Drugs Ther. 2026 Apr 13; 68(1752):57-9 doi:10.58347/tml.2026.1752a
The FDA has approved pivmecillinam ( Pivya – Utility Therapeutics), an oral penicillin-class antibacterial drug, for treatment of uncomplicated urinary tract infections (uUTIs) caused by susceptible isolates of Escherichia coli, Proteus mirabilis , or Staphylococcus saprophyticus in adult females. Pivmecillinam was approved by the FDA in 2024 but only recently became available in the US. It has been used in Europe for over 40 years.
Issue 1738 · September 29, 2025
IV Meloxicam Returns for Treatment of Pain

The FDA has approved Xifyrm (Azurity) and Qamzova (Nanjing Delova), two new intravenous (IV) formulations of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam, for use alone or in combination with…

Med Lett Drugs Ther. 2025 Sep 29; 67(1738):158-60 doi:10.58347/tml.2025.1738b
The FDA has approved Xifyrm (Azurity) and Qamzova (Nanjing Delova), two new intravenous (IV) formulations of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam, for use alone or in combination with non-NSAID analgesics for treatment of moderate to severe pain in adults. Anjeso , the first IV formulation of meloxicam, was discontinued in 2022 for commercial reasons.
Issue 1701 · April 29, 2024
Intravenous Acetaminophen/Ibuprofen (Combogesic IV)

The FDA has approved Combogesic IV (Hikma), an IV solution containing acetaminophen and ibuprofen, to treat mild to moderate pain (alone) or moderate to severe pain (in combination with an opioid) in adults…

Med Lett Drugs Ther. 2024 Apr 29; 66(1701):68-9 doi:10.58347/tml.2024.1701c
The FDA has approved Combogesic IV (Hikma), an IV solution containing acetaminophen and ibuprofen, to treat mild to moderate pain (alone) or moderate to severe pain (in combination with an opioid) in adults when IV analgesia is considered clinically necessary. Single-drug IV solutions containing ibuprofen (Caldolor) and acetaminophen have been available in the US for years.
Issue 1688 · October 30, 2023
Drugs for Gout

Drugs for gout are used to reduce the pain and inflammation of acute flares, decrease the frequency of exacerbations, and lower serum urate levels to prevent recurrent flares, development of tophi, and joint…

Med Lett Drugs Ther. 2023 Oct 30; 65(1688):169-75 doi:10.58347/tml.2023.1688a
Drugs for gout are used to reduce the pain and inflammation of acute flares, decrease the frequency of exacerbations, and lower serum urate levels to prevent recurrent flares, development of tophi, and joint damage.
Issue 1688 · October 30, 2023
Comparison Table: Some Drugs for Gout (online only)

View the Comparison Table: Some Drugs for Gout

Med Lett Drugs Ther. 2023 Oct 30; 65(1688):e176-9 doi:10.58347/tml.2023.1688c
View the Comparison Table: Some Drugs for Gout
Issue 1678 · June 12, 2023 Free
Drugs for Migraine

An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine pain without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe…

Med Lett Drugs Ther. 2023 Jun 12; 65(1678):89-96 doi:10.58347/tml.2023.1678a
An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine pain without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe migraine in most patients without vascular disease. Treatment of pain when it is still mild to moderate in intensity improves headache response and reduces the risk of recurrence.
Issue 1647 · April 4, 2022
Comparison Table: H2-Receptor Antagonists and PPIs (online only)

View the Comparison Table: H2-Receptor Antagonists and PPIs

Med Lett Drugs Ther. 2022 Apr 4; 64(1647):e56-7
View the Comparison Table: H2-Receptor Antagonists and PPIs
Issue 1645 · March 7, 2022
Comparison Table: Some Nonopioid Analgesics for Pain (online only)

View the Comparison Table: Some Nonopioid Analgesics for Pain

Med Lett Drugs Ther. 2022 Mar 7; 64(1645):e40-3
View the Comparison Table: Some Nonopioid Analgesics for Pain
Issue 1645 · March 7, 2022
Nonopioid Drugs for Pain

Nonopioid drugs can be used in the treatment of many nociceptive and neuropathic pain conditions. For severe pain, especially severe chronic cancer pain, use of opioids may be necessary. Noninvasive…

Med Lett Drugs Ther. 2022 Mar 7; 64(1645):33-40
Nonopioid drugs can be used in the treatment of many nociceptive and neuropathic pain conditions. For severe pain, especially severe chronic cancer pain, use of opioids may be necessary. Noninvasive nonpharmacologic treatments, including physical and psychological therapies, have been shown to improve pain and function in patients with some common chronic pain conditions and are unlikely to cause serious harms. A multimodal approach to analgesic therapy can increase pain control while reducing opioid use and adverse effects.
Issue 1643 · February 7, 2022
Drugs for Acute Otitis Media in Children

More antibiotics are prescribed for treatment of acute otitis media (AOM) than for any other infection in young children. Children with AOM typically present with otalgia, fever, and bulging and erythema of…

Med Lett Drugs Ther. 2022 Feb 7; 64(1643):22-3
More antibiotics are prescribed for treatment of acute otitis media (AOM) than for any other infection in young children. Children with AOM typically present with otalgia, fever, and bulging and erythema of the tympanic membrane.
Issue 1608 · October 5, 2020
Drugs for Migraine

An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine headache without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe…

Med Lett Drugs Ther. 2020 Oct 5; 62(1608):153-60
An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine headache without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe migraine headache pain in most patients without vascular disease. Early treatment of pain when it is still mild to moderate in intensity improves headache response and reduces the risk of recurrence.
Issue 1601 · June 29, 2020
IV Meloxicam (Anjeso) for Pain

The FDA has approved Anjeso (Baudax Bio), an IV formulation of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam, for once-daily treatment of moderate to severe pain in adults. Oral meloxicam ( Mobic ,…

Med Lett Drugs Ther. 2020 Jun 29; 62(1601):100-2
The FDA has approved Anjeso (Baudax Bio), an IV formulation of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam, for once-daily treatment of moderate to severe pain in adults. Oral meloxicam ( Mobic , and others), which is only indicated for treatment of chronic pain associated with osteoarthritis or rheumatoid arthritis, has been available for 20 years. IV formulations of ketorolac, ibuprofen (Caldolor) , and acetaminophen (Ofirmev) are also available for treatment of pain.
Issue 1596 · April 20, 2020
Drugs for Osteoarthritis

Many different drugs are used for treatment of osteoarthritis pain, but none of them prevent progression of the disease. Nonpharmacologic approaches including weight management, exercise, tai chi, physical…

Med Lett Drugs Ther. 2020 Apr 20; 62(1596):57-62
Many different drugs are used for treatment of osteoarthritis pain, but none of them prevent progression of the disease. Nonpharmacologic approaches including weight management, exercise, tai chi, physical therapy, assistive devices, and total joint arthroplasty can also be used. The American College of Rheumatology (ACR) has published new guidelines for the management of osteoarthritis of the hip, hand, and knee.
Issue 1595 · April 6, 2020 Free
Some Drugs for COVID-19

The severity and rapid spread of COVID-19 (caused by SARS-CoV-2) have raised questions about the use of some drugs in patients with the disease and whether currently available drugs could be effective in…

Med Lett Drugs Ther. 2020 Apr 6; 62(1595):49-50
The severity and rapid spread of COVID-19 (caused by SARS-CoV-2) have raised questions about the use of some drugs in patients with the disease and whether currently available drugs could be effective in treating it. Definitive answers are lacking, but some recommendations can be made. For additional information on specific drugs, see our table Some Drugs Being Considered for Treatment of COVID-19.
Issue 1595 · April 6, 2020 Free
Table: Treatments Considered for COVID-19 (Archived) (online only)

View the Table: Treatments Considered for COVID-19

Med Lett Drugs Ther. 2020 Apr 6; 62(1595):e1-289
View the Table: Treatments Considered for COVID-19
Issue 1919 · April 6, 2020 Free
Some Drugs for COVID-19

The severity and rapid spread of COVID-19 (caused by SARS-CoV-2) have raised questions about the use of some drugs in patients with the disease and whether currently available drugs could be effective in…

Med Lett Drugs Ther. 2020 Apr 6; 62(1919):1 doi:10.58347/tml.2020.1919a
The severity and rapid spread of COVID-19 (caused by SARS-CoV-2) have raised questions about the use of some drugs in patients with the disease and whether currently available drugs could be effective in treating it. Definitive answers are lacking, but some recommendations can be made. For additional information on specific drugs, see our table Some Drugs Being Considered for Treatment of COVID-19.
Issue 1582 · October 7, 2019
Advice for Travelers

Patients who receive pretravel advice can reduce their risk for many travel-related conditions. Vaccines recommended for travelers are reviewed in a separate issue.

Med Lett Drugs Ther. 2019 Oct 7; 61(1582):153-60
Patients who receive pretravel advice can reduce their risk for many travel-related conditions. Vaccines recommended for travelers are reviewed in a separate issue.
Issue 1582 · October 7, 2019
Expanded Table: Some Drugs for Altitude Illness, Jet Lag, and Motion Sickness (online only)

View the Expanded Table: Some Drugs for Altitude Illness, Jet Lag, and Motion Sickness

Med Lett Drugs Ther. 2019 Oct 7; 61(1582):e161-3
View the Expanded Table: Some Drugs for Altitude Illness, Jet Lag, and Motion Sickness
Issue 1576 · July 15, 2019
Benzhydrocodone/Acetaminophen (Apadaz) for Pain

The FDA has approved Apadaz (KemPharm), a short-acting, fixed-dose combination of benzhydrocodone and acetaminophen, for short-term management (≤14 days) of acute pain severe enough to require an opioid and…

Med Lett Drugs Ther. 2019 Jul 15; 61(1576):110-2
The FDA has approved Apadaz (KemPharm), a short-acting, fixed-dose combination of benzhydrocodone and acetaminophen, for short-term management (≤14 days) of acute pain severe enough to require an opioid and for which alternative treatment options are inadequate. Benzhydrocodone is a prodrug of hydrocodone. Fixed-dose combinations of short-acting hydrocodone and acetaminophen or ibuprofen have been available for years and are the most abused opioid products in the US. Apadaz was developed under the presumption that inclusion of the inactive prodrug would reduce the potential for abuse of the combination by non-oral routes such as smoking, snorting, or injection, but the FDA did not approve Apadaz as an abuse-deterrent formulation.
Issue 1567 · March 11, 2019
Drugs for Gout

Drugs for gout reduce the pain and inflammation of acute flares and lower serum urate levels in order to prevent recurrent flares, development of tophi, and joint damage.

Med Lett Drugs Ther. 2019 Mar 11; 61(1567):33-7
Drugs for gout reduce the pain and inflammation of acute flares and lower serum urate levels in order to prevent recurrent flares, development of tophi, and joint damage.
Issue 1567 · March 11, 2019
Expanded Table: Some Drugs for Gout (online only)

View the Expanded Table: Some Drugs for Gout

Med Lett Drugs Ther. 2019 Mar 11; 61(1567):e40-3
View the Expanded Table: Some Drugs for Gout
Issue 1540 · February 12, 2018
Nonopioid Drugs for Pain

Nonopioid drugs can be used in the treatment of many nociceptive and neuropathic pain conditions. Use of opioids for pain will be reviewed in a future issue.

Med Lett Drugs Ther. 2018 Feb 12; 60(1540):24-32
Nonopioid drugs can be used in the treatment of many nociceptive and neuropathic pain conditions. Use of opioids for pain will be reviewed in a future issue.
Issue 1540 · February 12, 2018
Comparison Table: Some Nonopioid Analgesics for Pain (online only)

View the Comparison Table: Some Nonopioid Analgesics for Pain

Med Lett Drugs Ther. 2018 Feb 12; 60(1540):e32-5
View the Comparison Table: Some Nonopioid Analgesics for Pain
Issue 1538 · January 15, 2018
Comparison Table: Drugs for GERD and Peptic Ulcer Disease (online only)

View the Comparison Table: Drugs for GERD and Peptic Ulcer Disease

Med Lett Drugs Ther. 2018 Jan 15; 60(1538):e16-8
View the Comparison Table: Drugs for GERD and Peptic Ulcer Disease
Issue 1514 · February 13, 2017
Drugs for Migraine

An oral nonopioid analgesic may be sufficient for treatment of mild to moderate migraine without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe migraine. Use of…

Med Lett Drugs Ther. 2017 Feb 13; 59(1514):27-32
An oral nonopioid analgesic may be sufficient for treatment of mild to moderate migraine without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe migraine. Use of a triptan early in an attack when pain is still mild to moderate in intensity improves headache response and reduces recurrence rates.
Issue 1510 · December 19, 2016
Celecoxib Safety Revisited

The results of a clinical trial (PRECISION) comparing the cardiovascular safety of the COX-2 selective NSAID celecoxib ( Celebrex , and generics) with that of ibuprofen and naproxen, which are nonselective,…

Med Lett Drugs Ther. 2016 Dec 19; 58(1510):159
The results of a clinical trial (PRECISION) comparing the cardiovascular safety of the COX-2 selective NSAID celecoxib ( Celebrex , and generics) with that of ibuprofen and naproxen, which are nonselective, have been described in the lay press in terms that may overestimate the safety of celecoxib.
Issue 1484 · December 21, 2015
Intravenous Diclofenac (Dyloject)

The FDA has approved Dyloject (Hospira), an IV formulation of the NSAID diclofenac sodium, for use in adults. It can be administered alone for treatment of mild to moderate pain or in combination with opioid…

Med Lett Drugs Ther. 2015 Dec 21; 57(1484):171-2
The FDA has approved Dyloject (Hospira), an IV formulation of the NSAID diclofenac sodium, for use in adults. It can be administered alone for treatment of mild to moderate pain or in combination with opioid analgesics for moderate to severe pain. Dyloject is the first injectable formulation of diclofenac to become available in the US.
Issue 1468 · May 11, 2015
Extended-Release Hydrocodone (Hysingla ER) for Pain

The FDA has approved a second extended-release (ER) formulation of the oral opioid agonist hydrocodone ( Hysingla ER – Purdue) for management of pain severe enough to require continuous long-term therapy and…

Med Lett Drugs Ther. 2015 May 11; 57(1468):71-2
The FDA has approved a second extended-release (ER) formulation of the oral opioid agonist hydrocodone ( Hysingla ER – Purdue) for management of pain severe enough to require continuous long-term therapy and for which alternative treatment options are inadequate. Hysingla ER tablets have abuse-deterrent properties to discourage their misuse.
Issue 1453 · October 13, 2014
Rescheduling of Hydrocodone Combination Products

The Drug Enforcement Administration (DEA) has reclassified all hydrocodone combination products as schedule II controlled substances; they were previously classified as schedule III. Hydrocodone alone (Zohydro…

Med Lett Drugs Ther. 2014 Oct 13; 56(1453):101-2
The Drug Enforcement Administration (DEA) has reclassified all hydrocodone combination products as schedule II controlled substances; they were previously classified as schedule III. Hydrocodone alone (Zohydro ER) is already a schedule II controlled substance.
Issue 1450 · September 1, 2014
Drugs for Osteoarthritis

Many different drugs are used for treatment of osteoarthritis pain, but none of them prevent progression of the disease. Many nonpharmacologic approaches are available as well, including weight management,…

Med Lett Drugs Ther. 2014 Sep 1; 56(1450):80-4
Many different drugs are used for treatment of osteoarthritis pain, but none of them prevent progression of the disease. Many nonpharmacologic approaches are available as well, including weight management, exercise, physical therapy, assistive devices, and total joint arthroplasty. New guidelines for the management of osteoarthritis have recently been published.
Issue 1447 · July 21, 2014
Extended-Release Oxycodone and Acetaminophen (Xartemis XR)

The FDA has approved a fixed-dose extended-release formulation of oxycodone and acetaminophen ( Xartemis XR – Mallinckrodt) for oral treatment of acute pain severe enough to require an opioid. Oxycodone is…

Med Lett Drugs Ther. 2014 Jul 21; 56(1447):59-61
The FDA has approved a fixed-dose extended-release formulation of oxycodone and acetaminophen ( Xartemis XR – Mallinckrodt) for oral treatment of acute pain severe enough to require an opioid. Oxycodone is available in the US as a single entity in oral immediate-release ( Oxecta , and others) and extendedrelease (OxyContin) formulations. Immediate-release oxycodone is also available in combination with aspirin ( Percodan , and others), acetaminophen ( Percocet , and others), or ibuprofen (see Table 1).
Issue 1447 · July 21, 2014 Free
In Brief: Generic Celecoxib

The FDA has authorized two manufacturers (Teva, Mylan) to market generic formulations of celecoxib ( Celebrex – Pfizer), the only COX-2 selective inhibitor remaining on the US market. Celecoxib is less…

Med Lett Drugs Ther. 2014 Jul 21; 56(1447):59
The FDA has authorized two manufacturers (Teva, Mylan) to market generic formulations of celecoxib ( Celebrex – Pfizer), the only COX-2 selective inhibitor remaining on the US market. Celecoxib is less likely than nonselective NSAIDs to cause gastric ulcers or other GI toxicity, 1 and unlike traditional NSAIDs, it does not have an antiplatelet effect. Celecoxib is much less COX-2 selective than rofecoxib (Vioxx) , which was removed from the US market because of an increased risk of cardiovascular events. One analysis of randomized clinical trials that included a total of about 26,000 patients taking celecoxib found no evidence of an increased risk of cardiovascular thrombotic events compared to nonselective NSAIDs or placebo. 2 A review of controlled observational studies found an increased cardiovascular risk with celecoxib (RR 1.17) that was similar to the risk with ibuprofen (RR 1.18) and slightly higher than the risk with naproxen (RR 1.09). 3 All NSAIDs can cause renal toxicity, especially in the elderly. 4 PL McCormack. Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Drugs 2011; 71:2457. WB White et al. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am J Cardiol 2007; 99:91. P McGettigan and D Henry. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 2011; 8:e1001098. RL Barkin et al. Should nonsteroidal anti-inflammatory drugs (NSAIDs) be prescribed to the older adult? Drugs Aging 2010; 27:775. Download complete U.S. English article
Issue 1444 · June 9, 2014
Extended-Release Hydrocodone (Zohydro ER) for Pain

The FDA has approved an extended-release oral formulation of the opioid agonist hydrocodone ( Zohydro ER – Zogenix) for management of pain severe enough to require continuous, long-term therapy and for which…

Med Lett Drugs Ther. 2014 Jun 9; 56(1444):45
The FDA has approved an extended-release oral formulation of the opioid agonist hydrocodone ( Zohydro ER – Zogenix) for management of pain severe enough to require continuous, long-term therapy and for which alternative treatment options are inadequate. Zohydro ER is the first single-ingredient hydrocodone product to be marketed in the US. Hydrocodone has been available for years in combination with acetaminophen ( Vicodin , and others) or ibuprofen ( Vicoprofen , and others).
Issue 136 · December 1, 2013
Drugs for Migraine

Treatment of migraine in the emergency department, which may involve use of intravenous drugs, is not discussed here.

Treat Guidel Med Lett. 2013 Dec; 11(136):107-12
Treatment of migraine in the emergency department, which may involve use of intravenous drugs, is not discussed here.
Issue 128 · April 1, 2013
Drugs for Pain

Pain can be acute or chronic. The two major types of chronic pain are nociceptive pain and neuropathic pain. Nociceptive pain can be treated with nonopioid analgesics or opioids. Neuropathic pain is less…

Treat Guidel Med Lett. 2013 Apr; 11(128):31-42
Pain can be acute or chronic. The two major types of chronic pain are nociceptive pain and neuropathic pain. Nociceptive pain can be treated with nonopioid analgesics or opioids. Neuropathic pain is less responsive to opioids and is often treated with adjuvant drugs such as antidepressants and antiepileptics. Combining different types of analgesics may provide an additive analgesic effect without increasing adverse effects.
Issue 117 · May 1, 2012
Drugs for Rheumatoid Arthritis

Disease-modifying anti-rheumatic drugs (DMARDs) are now used early in the treatment of rheumatoid arthritis (RA) to achieve clinical remission, prevent irreversible damage to joints, and minimize toxicity…

Treat Guidel Med Lett. 2012 May; 10(117):37-44
Disease-modifying anti-rheumatic drugs (DMARDs) are now used early in the treatment of rheumatoid arthritis (RA) to achieve clinical remission, prevent irreversible damage to joints, and minimize toxicity associated with nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. DMARDs (Table 1) generally do not have an immediate analgesic effect, but over time can control symptoms and have been shown to delay and possibly stop progression of the disease. NSAIDs have immediate analgesic and antiinflammatory effects, but may not affect the disease process. Oral corticosteroids can relieve joint symptoms and control systemic manifestations, but their chronic use can cause many complications. Judicious use of intra-articular corticosteroids can rapidly decrease inflammation in acute joints with few, if any, adverse effects.
Issue 1376 · October 31, 2011
A Fixed-Dose Combination of Ibuprofen and Famotidine (Duexis)

The FDA has approved Duexis (Horizon), a fixed-dose combination of the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen and the H2-receptor antagonist (H2RA) famotidine, for symptomatic relief of…

Med Lett Drugs Ther. 2011 Oct 31; 53(1376):85-6
The FDA has approved Duexis (Horizon), a fixed-dose combination of the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen and the H2-receptor antagonist (H2RA) famotidine, for symptomatic relief of osteoarthritis and rheumatoid arthritis and to decrease the risk of developing gastric and duodenal ulcers in patients at risk for NSAID-associated ulcers. Vimovo , a combination of the NSAID naproxen and the proton pump inhibitor (PPI) esomeprazole, is also approved by the FDA for prevention of NSAID-associated gastric ulcers.
Issue 102 · February 1, 2011
Drugs for Migraine

Drugs for treatment of migraine are listed in Table 2 on page 9. Drugs for prevention of migraine are listed in Table 3 on page 10. Treatment of migraine in the emergency room, which may involve use of…

Treat Guidel Med Lett. 2011 Feb; 9(102):7-12
Drugs for treatment of migraine are listed in Table 2 on page 9. Drugs for prevention of migraine are listed in Table 3 on page 10. Treatment of migraine in the emergency room, which may involve use of intravenous drugs, is not included here.
Issue 1346 · September 6, 2010 Free
In Brief: Propoxyphene Toxicity

The FDA has required manufacturers of propoxyphene-containing products ( Darvon , and others) to strengthen boxed warnings to include the potential for overdose. 1 This action followed disclosure of fatal…

Med Lett Drugs Ther. 2010 Sep 6; 52(1346):69
The FDA has required manufacturers of propoxyphene-containing products ( Darvon , and others) to strengthen boxed warnings to include the potential for overdose. 1 This action followed disclosure of fatal overdoses linked to propoxyphene-containing products taken alone or concurrently with other CNS depressants, including alcohol. Many of the overdoses occurred in patients with a history of emotional instability or suicide attempts. Accumulation of metabolites of propoxyphene can lead to central nervous system, cardiac and respiratory depression; convulsions and cardiotoxicity have occurred. A Schedule IV controlled substance, propoxyphene is a weak full agonist opioid indicated for relief of mild to moderate pain. 2 It is often prescribed in combination with acetaminophen ( Darvocet , and others). One reasonable alternative would be codeine with acetaminophen; 32 mg of codeine has an analgesic effect similar to that of 65 mg of propoxyphene. Another would be 400 mg of ibuprofen, which may be more effective than either propoxyphene or codeine combined with acetaminophen. 1. FDA News Release. FDA takes actions on Darvon, other pain medications containing propoxyphene. Available at www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm170769.html. Accessed August 23, 2010. 2. Drugs for pain. Treat Guidel Med Lett 2010; 92:25 . Download: U.S. English
Issue 92 · April 1, 2010
Drugs for Pain

Pain can be acute or chronic. Chronic pain has been broadly classified into two types: nociceptive and neuropathic. Nociceptive pain can be treated with nonopioid analgesics or opioids. Neuropathic pain is…

Treat Guidel Med Lett. 2010 Apr; 8(92):25-34
Pain can be acute or chronic. Chronic pain has been broadly classified into two types: nociceptive and neuropathic. Nociceptive pain can be treated with nonopioid analgesics or opioids. Neuropathic pain is less responsive to opioids; adjuvant medicines such as antidepressants and anticonvulsants are often used to treat neuropathic pain. Combining different types of analgesics may provide an additive analgesic effect without increasing adverse effects.
Issue 1326 · November 30, 2009
Colchicine and Other Drugs for Gout

Until the recent introduction of febuxostat (Uloric) , no new drugs had been marketed for treatment of gout in the past 40 years. Colchicine, which has been available for decades as an unapproved drug, has now…

Med Lett Drugs Ther. 2009 Nov 30; 51(1326):93-4
Until the recent introduction of febuxostat (Uloric) , no new drugs had been marketed for treatment of gout in the past 40 years. Colchicine, which has been available for decades as an unapproved drug, has now been approved by the FDA (Colcrys) for treatment and prophylaxis of gout flares. It was approved earlier only in combination with probenecid ( Colbenemid , and others). The goals of gout treatment are three-fold: treating acute disease, preventing flares and reducing uric acid stores.
Issue 81 · May 1, 2009
Drugs for Rheumatoid Arthritis

Disease-modifying anti-rheumatic drugs (DMARDs) are now used early in the treatment of rheumatoid arthritis (RA) to prevent irreversible damage to joints and minimize toxicities associated with nonsteroidal…

Treat Guidel Med Lett. 2009 May; 7(81):37-46
Disease-modifying anti-rheumatic drugs (DMARDs) are now used early in the treatment of rheumatoid arthritis (RA) to prevent irreversible damage to joints and minimize toxicities associated with nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids.
Issue 1288 · June 16, 2008
A Fixed-Dose Combination of Sumatriptan and Naproxen for Migraine

The FDA has approved an oral, fixed-dose combination ( Treximet - GlaxoSmithKline) of the selective serotonin receptor agonist ("triptan") sumatriptan (Imitrex) and the nonsteroidal anti-inflammatory drug…

Med Lett Drugs Ther. 2008 Jun 16; 50(1288):45-6
The FDA has approved an oral, fixed-dose combination ( Treximet - GlaxoSmithKline) of the selective serotonin receptor agonist ("triptan") sumatriptan (Imitrex) and the nonsteroidal anti-inflammatory drug (NSAID) naproxen sodium ( Anaprox , and others) for acute treatment of migraine attacks.
Issue 67 · March 1, 2008
Drugs for Migraine

Some drugs for treatment of migraine attacks are listed in table 2 on page 18. Drugs for prevention of migraine are listed in table 3 on page 20. Treatment of migraine in the emergency room, which may involve…

Treat Guidel Med Lett. 2008 Mar; 6(67):17-22
Some drugs for treatment of migraine attacks are listed in table 2 on page 18. Drugs for prevention of migraine are listed in table 3 on page 20. Treatment of migraine in the emergency room, which may involve use of intravenous drugs, is not included here.
Issue 1277 · January 14, 2008
A Diclofenac Patch (Flector) for Pain

Diclofenac epolamine patch 1.3% ( Flector Patch - Alpharma), a topical formulation of the nonsteroidal anti-inflammatory drug (NSAID) diclofenac, has been approved by the FDA for topical treatment of acute…

Med Lett Drugs Ther. 2008 Jan 14; 50(1277):1-2
Diclofenac epolamine patch 1.3% ( Flector Patch - Alpharma), a topical formulation of the nonsteroidal anti-inflammatory drug (NSAID) diclofenac, has been approved by the FDA for topical treatment of acute pain due to minor strains, sprains and contusions. It is the first topical NSAID patch approved in the US. A diclofenac patch has been used in Europe since 1993. Diclofenac sodium ( Voltaren , and others) is available in the US as an oral tablet, in a 1% gel for treatment of osteoarthritis (to be reviewed in a future issue), in a 3% gel ( Solaraze ) for treatment of actinic keratoses, and in an ophthalmic formulation.
Issue 56 · April 1, 2007
Drugs for Pain

Pain can be acute or chronic. Chronic pain has been broadly classified into two types: nociceptive and neuropathic. Nociceptive pain is generally treated with nonopioid analgesics and opioids. Antidepressants…

Treat Guidel Med Lett. 2007 Apr; 5(56):23-32
Pain can be acute or chronic. Chronic pain has been broadly classified into two types: nociceptive and neuropathic. Nociceptive pain is generally treated with nonopioid analgesics and opioids. Antidepressants and anticonvulsants have been used to treat neuropathic pain. Combining two different types of analgesics may nprovide an additive analgesic effect without increasing adverse effects.
Issue 1225 · January 2, 2006
A Combination of Oxycodone and Ibuprofen (Combunox) for Pain

A fixed-dose combination of oxycodone 5 mg and ibuprofen 400 mg ( Combunox - Forest Laboratories) is now available and is being heavily advertised for short-term treatment of moderate to severe acute pain.

Med Lett Drugs Ther. 2006 Jan 2; 48(1225):3-4
A fixed-dose combination of oxycodone 5 mg and ibuprofen 400 mg ( Combunox - Forest Laboratories) is now available and is being heavily advertised for short-term treatment of moderate to severe acute pain.
Issue 40 · December 1, 2005
Drugs for Rheumatoid Arthritis

To prevent irreversible damage to joints and minimize toxicities associated with nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, disease modifying anti-rheumatic drugs (DMARDs) are now used…

Treat Guidel Med Lett. 2005 Dec; 3(40):83-90
To prevent irreversible damage to joints and minimize toxicities associated with nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, disease modifying anti-rheumatic drugs (DMARDs) are now used early in the treatment of rheumatoid arthritis (RA). The DMARDs listed in the table on page 84 have no immediate analgesic effects, but can control symptoms and have been shown to delay and possibly stop progression of the disease. The NSAIDs listed in the table on page 88 have analgesic and anti-inflammatory effects, but may not affect the disease process. Oral corticosteroids can rapidly relieve joint symptoms and control systemic manifestations, but their chronic use is associated with many complications.
Issue 1195 · November 8, 2004
COX-2 Alternatives and GI Protection

With the removal of Vioxx from the market and concerns about cardiovascular toxicity with other selective COX-2 inhibitors, patients are looking for safe alternatives, and manufacturers of other drugs are…

Med Lett Drugs Ther. 2004 Nov 8; 46(1195):91-2
With the removal of Vioxx from the market and concerns about cardiovascular toxicity with other selective COX-2 inhibitors, patients are looking for safe alternatives, and manufacturers of other drugs are looking for additional market share. The COX-2 inhibitors first became popular because they have less upper GI toxicity than older less selective NSAIDs, at least in the short term, in patients not taking aspirin.
Issue 1194 · October 25, 2004
What About Celebrex?

Rofecoxib ( Vioxx - Merck) has been withdrawn from the market due to an increased risk of cardiovascular complications associated with its long-term use. The question remains whether all selective COX-2…

Med Lett Drugs Ther. 2004 Oct 25; 46(1194):87-8
Rofecoxib ( Vioxx - Merck) has been withdrawn from the market due to an increased risk of cardiovascular complications associated with its long-term use. The question remains whether all selective COX-2 inhibitors carry the same risk. Full-page advertisements in newspapers for celecoxib ( Celebrex - Pfizer), the most widely used COX-2 inhibitor, assure the public that it does not.
Issue 25 · September 1, 2004
Drugs for Migraine

Drugs for treatment of migraine attacks are listed in the table on page 64. All of the oral drugs are most effective if taken early in an attack when the pain is mild (H Christoph-Diener et al, Neurology 2004;…

Treat Guidel Med Lett. 2004 Sep; 2(25):63-6
Drugs for treatment of migraine attacks are listed in the table on page 64. All of the oral drugs are most effective if taken early in an attack when the pain is mild (H Christoph-Diener et al, Neurology 2004; 63:520). Drugs for prevention of migraine are listed in the table on page 65. Treatment of migraine in the emergency room, which may involve use of intravenous drugs, is not included here.
Issue 1188 · August 2, 2004
Do NSAIDs Interfere with the Cardioprotective Effects of Aspirin?

Low-dose aspirin is widely used as an antiplatelet drug to reduce the risk of cardiovascular disease ( Medical Letter 2000; 42:18 ). Recent reports suggest that the nonsteroidal anti-inflammatory drug (NSAID)…

Med Lett Drugs Ther. 2004 Aug 2; 46(1188):61-2
Low-dose aspirin is widely used as an antiplatelet drug to reduce the risk of cardiovascular disease ( Medical Letter 2000; 42:18 ). Recent reports suggest that the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen ( Motrin , and others) may decrease the efficacy of aspirin for this indication. The manufacturer of Tylenol is capitalizing on these reports by advertising that aspirin-taking patients who need pain relief should use acetaminophen instead of ibuprofen.
Issue 23 · July 1, 2004
Drugs for Pain

Three types of analgesic drugs are available: non-opioids, including aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; opioids; and adjuvant drugs that are not usually thought of…

Treat Guidel Med Lett. 2004 Jul; 2(23):47-54
Three types of analgesic drugs are available: non-opioids, including aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; opioids; and adjuvant drugs that are not usually thought of as analgesics, such as antidepressants, which can act as adjuvants when given with NSAIDs or opioids, or have analgesic activity of their own in some types of pain. Combining two different types of analgesics may provide an additive analgesic effect without necessarily increasing adverse effects.
Issue 1184 · June 7, 2004 Free
Prevention and Treatment of Sunburn

Solar ultraviolet (UV) light capable of injuring the skin is classified by wavelength into UVA I (340-400 nm), UVA II (320-340 nm) and UVB (290-320 nm). UVB is responsible for most of the erythema of sunburn.…

Med Lett Drugs Ther. 2004 Jun 7; 46(1184):45-6
Solar ultraviolet (UV) light capable of injuring the skin is classified by wavelength into UVA I (340-400 nm), UVA II (320-340 nm) and UVB (290-320 nm). UVB is responsible for most of the erythema of sunburn. UVA has been implicated in the development of phototoxicity and photoaging. The FDA permits sunscreen manufacturers to claim broad-spectrum protection if their products block at least part of UVA II in addition to UVB. Click here to view the free full article.
Issue 1158 · June 8, 2003
Drug Interactions

Changes caused by one drug in the absorption, distribution, metabolism or excretion of another may lead to a pharmacokinetic adverse drug interaction (DN Juurlink et al, JAMA 2003; 289:1652). Additive drug…

Med Lett Drugs Ther. 2003 Jun 8; 45(1158):46-8
Changes caused by one drug in the absorption, distribution, metabolism or excretion of another may lead to a pharmacokinetic adverse drug interaction (DN Juurlink et al, JAMA 2003; 289:1652). Additive drug interactions, such as vasodilation caused by both sildenafil (Viagra) and nitrates, can also have adverse effects.
Issue 5 · January 1, 2003
Drugs for Rheumatoid Arthritis

Many different drugs are now used to treat rheumatoid arthritis. Nonsteroidal anti-inflammatory drugs (NSAIDs), listed in the table on page 26, have analgesic and anti-inflammatory effects, but may not affect…

Treat Guidel Med Lett. 2003 Jan; 1(5):25-32
Many different drugs are now used to treat rheumatoid arthritis. Nonsteroidal anti-inflammatory drugs (NSAIDs), listed in the table on page 26, have analgesic and anti-inflammatory effects, but may not affect the disease process. Corticosteroids can provide rapid relief of joint symptoms and control of systemic manifestations, but chronic use is associated with many complications. The "disease-modifying" anti-rheumatic drugs (DMARDs), listed on page 29, have no immediate analgesic effects, but can control symptoms and may delay progression of the disease (American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines, Arthritis Rheum 2002; 46:328). Interactions of anti-rheumatic drugs with other drugs are listed in The Medical Letter Handbook of Adverse Drug Interactions, 2003.
Issue 1141 · October 14, 2002
Generic drugs

When patents expire on brand-name drugs and generic formulations become available, patients and managed care organizations may express a preference for the lower-cost generics. Are they equivalent to the…

Med Lett Drugs Ther. 2002 Oct 14; 44(1141):89-90
When patents expire on brand-name drugs and generic formulations become available, patients and managed care organizations may express a preference for the lower-cost generics. Are they equivalent to the brand-name product?
Issue 1129 · April 29, 2002
Valdecoxib (Bextra) - a New Cyclooxygenase-2 Inhibitor

Valdecoxib ( Bextra - Pharmacia/Pfizer), a selective cyclooxygenase (COX-2) inhibitor similar to celecoxib (Celebrex) and rofecoxib (Vioxx) , was recently approved by the FDA for treatment of osteoarthritis,…

Med Lett Drugs Ther. 2002 Apr 29; 44(1129):39-41
Valdecoxib ( Bextra - Pharmacia/Pfizer), a selective cyclooxygenase (COX-2) inhibitor similar to celecoxib (Celebrex) and rofecoxib (Vioxx) , was recently approved by the FDA for treatment of osteoarthritis, rheumatoid arthritis and primary dysmenorrhea.
Issue 1118 · November 12, 2001
Cardiovascular Safety of Cox-2 Inhibitors

Related Articles Since Publication Increasing use of rofecoxib (Vioxx) and celecoxib (Celebrex) , both selective inhibitors of cyclooxygenase-2 (COX-2), for treatment of arthristis has been accompanied by…

Med Lett Drugs Ther. 2001 Nov 12; 43(1118):99-100
Related Articles Since Publication Increasing use of rofecoxib (Vioxx) and celecoxib (Celebrex) , both selective inhibitors of cyclooxygenase-2 (COX-2), for treatment of arthristis has been accompanied by concerns that they may increase risk of thrombotic cardiovascular events.
Issue 1085 · August 21, 2000
Drugs for Pain

Three types of analgesic drugs are available: first, non-opioids, including aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; second, opioids; and third, drugs not usually thought…

Med Lett Drugs Ther. 2000 Aug 21; 42(1085):73-8
Three types of analgesic drugs are available: first, non-opioids, including aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; second, opioids; and third, drugs not usually thought of as analgesics, which act as adjuvants when given with NSAIDs or opioids, or have analgesic activity of their own in some types of pain. Non-opioids can be given concurrently with opioids for an additive analgesic effect.
Issue 1082 · July 10, 2000
Drugs For Rheumatoid Arthritis

Many different drugs are now used to treat rheumatoid arthritis. Nonsteroidal anti-inflammatory drugs (NSAIDs) have analgesic and anti-inflammatory effects, but may not affect the disease process. The…

Med Lett Drugs Ther. 2000 Jul 10; 42(1082):57-64
Many different drugs are now used to treat rheumatoid arthritis. Nonsteroidal anti-inflammatory drugs (NSAIDs) have analgesic and anti-inflammatory effects, but may not affect the disease process. The "disease-modifying anti-rheumatic"drugs (DMARDs) have no immediate analgesic effects, but can control symptoms and may delay progression of the disease.
Issue 1079 · May 29, 2000
Meloxicam (Mobic) for Osteoarthritis

Meloxicam, a nonsteroidal anti-inflammatory drug (NSAID) with some cyclooxygenase-2 (COX-2) selectivity in vitro, has been approved by the FDA for treatment of osteoarthritis.

Med Lett Drugs Ther. 2000 May 29; 42(1079):47-8
Meloxicam, a nonsteroidal anti-inflammatory drug (NSAID) with some cyclooxygenase-2 (COX-2) selectivity in vitro, has been approved by the FDA for treatment of osteoarthritis.
Issue 1056 · July 2, 1999
Rofecoxib for Osteoarthritis and Pain

Rofecoxib, a selective COX-2 inhibitor, has been approved by the FDA for treatment of osteoarthritis, acute pain and menstrual pain.

Med Lett Drugs Ther. 1999 Jul 2; 41(1056):59-62
Rofecoxib, a selective COX-2 inhibitor, has been approved by the FDA for treatment of osteoarthritis, acute pain and menstrual pain.
Issue 1056 · July 2, 1999
Drug Interactions

Reports of adverse interactions between drugs continue to accumulate. Recently, the FDA has expanded the recommendations on drug interactions found in the package inserts of new drugs.

Med Lett Drugs Ther. 1999 Jul 2; 41(1056):59-62
Reports of adverse interactions between drugs continue to accumulate. Recently, the FDA has expanded the recommendations on drug interactions found in the package inserts of new drugs.
Issue 1045 · January 29, 1999
Celecoxib for Arthritis

Celecoxib, a selective COX-2 inhibitor, has been approved by the FDA for treatment of osteoarthritis and rheumatoid arthritis.

Med Lett Drugs Ther. 1999 Jan 29; 41(1045):11-2
Celecoxib, a selective COX-2 inhibitor, has been approved by the FDA for treatment of osteoarthritis and rheumatoid arthritis.
Issue 1040 · November 20, 1998
New Drugs for Rheumatoid Arthritis

Leflunomide ( Arava - Hoechst Marion Roussel), which inhibits pyrimidine synthesis, and etanercept ( Enbrel - Immunex/Wyeth-Ayerst), which blocks the action of tumor necrosis factor (TNF), have been approved…

Med Lett Drugs Ther. 1998 Nov 20; 40(1040):110-2
Leflunomide ( Arava - Hoechst Marion Roussel), which inhibits pyrimidine synthesis, and etanercept ( Enbrel - Immunex/Wyeth-Ayerst), which blocks the action of tumor necrosis factor (TNF), have been approved by the FDA for treatment of rheumatoid arthritis. A third drug, infliximab ( Remicade - Centocor), which also blocks TNF and has been used to treat rheumatoid arthritis, was approved earlier for treatment of Crohn's disease. Its use in Crohn's disease will be reviewed in a future issue.
Issue 1033 · August 14, 1998
Drugs for Pain

Three types of analgesic drugs are available: first, non-opioids, including aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; second, opioids; and third, some drugs not usually…

Med Lett Drugs Ther. 1998 Aug 14; 40(1033):79-84
Three types of analgesic drugs are available: first, non-opioids, including aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; second, opioids; and third, some drugs not usually thought of as analgesics, which act as adjuvants when given with NSAIDs or opioids, or have analgesic activity of their own in some types of pain.
Issue 1011 · October 10, 1997
Bromfenac for Analgesia

Bromfenac sodium ( Duract - Wyeth-Ayerst), a nonsteroidal anti-inflammatory drug (NSAID), has been approved by the US Food and Drug Administration (FDA) and is being heavily advertised as an alternative to…

Med Lett Drugs Ther. 1997 Oct 10; 39(1011):93-4
Bromfenac sodium ( Duract - Wyeth-Ayerst), a nonsteroidal anti-inflammatory drug (NSAID), has been approved by the US Food and Drug Administration (FDA) and is being heavily advertised as an alternative to narcotics for short-term treatment of pain.
Issue 1010 · September 26, 1997
Glucosamine for Osteoarthritis

The Medical Letter has received many inquiries about use of glucosamine, a basic constituent of articular cartilage glycosaminoglycans, for treatment of arthritis. A recently published book ( The Arthritis…

Med Lett Drugs Ther. 1997 Sep 26; 39(1010):91-2
The Medical Letter has received many inquiries about use of glucosamine, a basic constituent of articular cartilage glycosaminoglycans, for treatment of arthritis. A recently published book ( The Arthritis Cure ), several television news shows, and articles in The New York Times have suggested it may be effective for treatment of osteoarthritis. Glucosamine is sold as a 'dietary supplement' in the USA.
Issue 977 · June 21, 1996
Acetaminophen, Nsaids and Alcohol

An advertising war between manufacturers of over-the-counter (OTC) analgesics has led some patients to ask their physicians about the safety of taking these products if they also drink alcohol.

Med Lett Drugs Ther. 1996 Jun 21; 38(977):55-6
An advertising war between manufacturers of over-the-counter (OTC) analgesics has led some patients to ask their physicians about the safety of taking these products if they also drink alcohol.
Issue 890 · February 19, 1993
Oxaprozin for Arthritis

Oxaprozin ( Daypro -Searle), a propionic acid-derivative nonsteroidal anti-inflammatory drug (NSAID), has been approved by the US Food and Drug Administration for once-daily treatment of rheumatoid arthritis…

Med Lett Drugs Ther. 1993 Feb 19; 35(890):15-6
Oxaprozin ( Daypro -Searle), a propionic acid-derivative nonsteroidal anti-inflammatory drug (NSAID), has been approved by the US Food and Drug Administration for once-daily treatment of rheumatoid arthritis and osteoarthritis. Some of the NSAIDs previously marketed in the USA are listed in the table on page 16. Ibuprofen, naproxen, fenoprofen, ketoprofen, and flurbiprofen are also propionic acid derivatives. Piroxicam and nabumetone (Medical Letter, 34:38, 1992) are also approved for once-daily use, and indomethacin is available in an extended-release formulation that can be taken once a day.
Issue 887 · January 8, 1993
Drugs for Pain

Three types of analgesic drugs are available in the USA: first, aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; second, opioids; and third, drugs not usually thought of as…

Med Lett Drugs Ther. 1993 Jan 8; 35(887):1-6
Three types of analgesic drugs are available in the USA: first, aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; second, opioids; and third, drugs not usually thought of as analgesics, which act as adjuvants when given with NSAIDs or opioids, or have analgesic activity of their own in some types of pain. (American Pain Society, Principles of analgesic Use , 3rd ed, Skokie, illinois: American pain society, 1992).
Issue 868 · April 17, 1992
Nabumetone - A New Nsaid

Nabumetone ( Relafen - SmithKline Beecham), a new nonsteroidal anti-inflammatory drug (NSAID), has been approved by the US Food and Drug Administration for treatment of rheumatoid arthritis and osteoarthritis.…

Med Lett Drugs Ther. 1992 Apr 17; 34(868):38-40
Nabumetone ( Relafen - SmithKline Beecham), a new nonsteroidal anti-inflammatory drug (NSAID), has been approved by the US Food and Drug Administration for treatment of rheumatoid arthritis and osteoarthritis. The drug has been available in the United Kingdom since 1987. The manufacturer claims that nabumetone is as effective as other NSAIDs and causes a relatively low incidence of peptic ulcers.
Issue 864 · February 21, 1992
Drugs For Treatment Of Fungal Infections

The incidence of opportunistic fungal infections continues to increase, particularly in patients who have AIDS, are taking immunosuppressive drugs, or are in intensive care units. Intravenous (IV) amphotericin…

Med Lett Drugs Ther. 1992 Feb 21; 34(864):14-6
The incidence of opportunistic fungal infections continues to increase, particularly in patients who have AIDS, are taking immunosuppressive drugs, or are in intensive care units. Intravenous (IV) amphotericin B ( Fungizone , and others), sometimes given with flucytosine ( Ancobon ), is the drug of choice for initial treatment of most rapidly progressive, acutely life-threatening fungal infections; for less severe infections, fluconazole ( Diflucan , ketoconazole ( Nizoral ), or itraconazole ( Sporanox - an investigational drug in the (USA) may also be effective, can be taken orally, and are much better tolerated. The treatment of superficial fungal infections is not discussed here.
Issue 851 · August 23, 1991
Etodolac

Etodolac ( Lodine - Wyeth-Ayerst), a nonsteroidal anti-inflammatory drug (NSAID) available in Europe for several years, was recently approved by the U.S. Food and Drug Administration for use in osteoarthritis…

Med Lett Drugs Ther. 1991 Aug 23; 33(851):79-80
Etodolac ( Lodine - Wyeth-Ayerst), a nonsteroidal anti-inflammatory drug (NSAID) available in Europe for several years, was recently approved by the U.S. Food and Drug Administration for use in osteoarthritis and as a general-purpose analgesic. It has not been approved for treatment of rheumatoid arthritis.
Issue 827 · September 21, 1990
Drugs That Cause Pulmonary Toxicity

Some commonly used systemic drugs that may cause pulmonary toxicity are listed in the table below. These adverse effects may sometimes be difficult to distinguish from the underlying disease (JAD Cooper, Jr et…

Med Lett Drugs Ther. 1990 Sep 21; 32(827):88-90
Some commonly used systemic drugs that may cause pulmonary toxicity are listed in the table below. These adverse effects may sometimes be difficult to distinguish from the underlying disease (JAD Cooper, Jr et al, Am Rev Respir Dis, 133:321, 488, 1986). Pulmonary effects that are part of a generalized reaction or are indirect effects of drugs - on respiratory muscles, for example, or on the immune system - are not included here.
Issue 807 · December 15, 1989
Ibuprofen vs. Acetaminophen in Children

Since the implication of aspirin in Reye's syndrome, acetaminophen ( Tylenol ; and others) has become the standard drug for symptomatic treatment of fever and pain in children. Ibuprofen, a nonsteroidal…

Med Lett Drugs Ther. 1989 Dec 15; 31(807):109-10
Since the implication of aspirin in Reye's syndrome, acetaminophen ( Tylenol ; and others) has become the standard drug for symptomatic treatment of fever and pain in children. Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID) available for many years in tables ( Mortin; Advil; and others), has now become available in a suspension. The suspension will be sold by presecription for treatment of fever or arthritis in children.
Issue 789 · April 7, 1989
Flurbiprofen

Flurbiprofen ( Ansaid - Upjohn), a nonsteroidal anti-inflammatory drug (NSAID) available in some countries since 1977, was recently approved by the US Food and Drug Administration for treatment of rheumatoid…

Med Lett Drugs Ther. 1989 Apr 7; 31(789):31-2
Flurbiprofen ( Ansaid - Upjohn), a nonsteroidal anti-inflammatory drug (NSAID) available in some countries since 1977, was recently approved by the US Food and Drug Administration for treatment of rheumatoid arthritis and osteoarthritis. Flurbiprofen is a fluorinated phenylalkanoic acid derivative structurally related to ibuprofen ( Motrin ;and others).
Issue 787 · March 10, 1989
Misoprostol

Misoprostol ( Cytotec - Searle), a synthetic methyl analog of prostaglandin E1, was recently approved by the US Food and Drug Administration for prevention of gastric ulcers in high-risk patients taking…

Med Lett Drugs Ther. 1989 Mar 10; 31(787):21-2
Misoprostol ( Cytotec - Searle), a synthetic methyl analog of prostaglandin E1, was recently approved by the US Food and Drug Administration for prevention of gastric ulcers in high-risk patients taking nonsteroidal anti-inflammatory drugs (NSAIDs). In other countries, the drug is also marketed for treatment of idiopathic peptic ulcers unrelated to NSAIDs.
Issue 780 · December 2, 1988
Diclofenac

Diclofenac sodium ( Voltaren - Geigy), a nonsteroidal anti-inflammatory drug (NSAID) available in some countries since 1974, was recently introduced in the USA for treatment of rheumatoid arthritis,…

Med Lett Drugs Ther. 1988 Dec 2; 30(780):109-11
Diclofenac sodium ( Voltaren - Geigy), a nonsteroidal anti-inflammatory drug (NSAID) available in some countries since 1974, was recently introduced in the USA for treatment of rheumatoid arthritis, osteoarthritis and ankylosing spondylitis. It is being promoted as 'The number one prescribed antiarthritic in the world.'